Monitor first-day trading performance and any subsequent clinical data updates for BHB-1893. The upsized IPO suggests strong institutional demand, but as a clinical-stage biotech, execution risk on pipeline milestones remains high.
Price Chart
Executive Summary
Braveheart Bio priced its upsized IPO of 21.25M shares at $18.00 per share, raising $382.5M in gross proceeds. The strong demand and upsized offering signal robust investor interest in the clinical-stage biopharma's lead HCM candidate, BHB-1893. Shares begin trading on Nasdaq on August 6, 2026.
Key Financial Metrics
Key Facts
- IPO of 21,250,000 shares at $18.00 per share, upsized from initial plans
- Gross proceeds of $382.5 million before expenses
- Underwriters have 30-day option for additional 3,187,500 shares
- Trading on Nasdaq under ticker BRVE begins August 6, 2026
- Lead candidate BHB-1893 is a next-generation cardiac myosin inhibitor for hypertrophic cardiomyopathy
Financial Impact
Gross proceeds of $382.5 million from IPO, providing substantial capital for clinical development of BHB-1893
Risk Factors
- Clinical-stage company with no approved products or revenue
- BHB-1893 faces competition from existing HCM therapies like Camzyos
- Need for successful clinical trials and regulatory approvals
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339895 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 3 | $27.66 $26.71 | ▼ −3.43% | ▼ −1.46% | $21.74 (−21.42%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.74 (−16.88%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.74 (−16.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.74 (−21.05%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.74 (−21.05%) |
Aug 5, 2026 11w ago | Press Release | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.74 (−27.06%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.74 (−27.06%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.74 (−27.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers